ArticleThe American journal of pathology1996
Down-regulation of beta 1C integrin, an inhibitor of cell proliferation, in prostate carcinoma.
Article in The American journal of pathology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 62 citations in OpenAlex.
- Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.Biochemical and biophysical research communications · 2014Article
- β4 Integrin signaling induces expansion of prostate tumor progenitors.The Journal of clinical investigation · 2013Article
- β1 integrin deletion enhances progression of prostate cancer in the TRAMP mouse model.Scientific reports · 2012Article
- A novel mutation in β integrin reveals an integrin-mediated interaction between the extracellular matrix and cki-1/p27KIP1.PloS one · 2012Article
- Prosaposin down-modulation decreases metastatic prostate cancer cell adhesion, migration, and invasion.Molecular cancer · 2010Article
- Beta1 integrin cytoplasmic variants differentially regulate expression of the antiangiogenic extracellular matrix protein thrombospondin 1.Cancer research · 2009Article
- Chemical and Biochemical Basis of Cell-Bone Matrix Interaction in Health and Disease.Current chemical biology · 2009Article
- Integrin signaling aberrations in prostate cancer.American journal of translational research · 2009Article
- Integrins in prostate cancer progression.Endocrine-related cancer · 2008Review
- New insights into syndecan-2 expression and tumourigenic activity in colon carcinoma cells.Journal of molecular histology · 2004Review
- beta 1C Integrin expression in human endometrial proliferative diseases.The American journal of pathology · 2003Article
- Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion.Oncogene · 2002Article
- Unique expression pattern of the alpha6beta4 integrin and laminin-5 in human prostate carcinoma.The Prostate · 2001Article
- Regulation of mRNA and protein levels of beta1 integrin variants in human prostate carcinoma.The American journal of pathology · 2000Article
- Differential role of beta(1C) and beta(1A) integrin cytoplasmic variants in modulating focal adhesion kinase, protein kinase B/AKT, and Ras/Mitogen-activated protein kinase pathways.Molecular biology of the cell · 2000Article
- Down-regulation of beta(1C) integrin in breast carcinomas correlates with high proliferative fraction, high histological grade, and larger size.The American journal of pathology · 2000Article
- p27(kip1) acts as a downstream effector of and is coexpressed with the beta1C integrin in prostatic adenocarcinoma.The Journal of clinical investigation · 1999Article
- Beta1C integrin in epithelial cells correlates with a nonproliferative phenotype: forced expression of beta1C inhibits prostate epithelial cell proliferation.The American journal of pathology · 1998Article
- Identification of beta1C-2, a novel variant of the integrin beta1 subunit generated by utilization of an alternative splice acceptor site in exon C.The Biochemical journal · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The beta 1C integrin, a member of the cell adhesion receptor superfamily, is an alternatively spliced variant of the beta 1A subunit and, in contrast to its wild-type counterpart, inhibits cell proliferation in vitro. The expression of beta 1C integrin in tumor cell growth was investigated. In benign and neoplastic human prostate tissues, immunohistochemical analysis performed using affinity-purified antibodies specific for beta 1C demonstrated a predominant epithelial expression of beta 1C in benign prostate glands with marked staining of the apical, basal, and lateral surfaces. In the adjacent prostate adenocarcinoma glands, the beta 1C variant was dramatically down-regulated in 27 of 34 (79%) analyzed cases, whereas the expression and distribution of its wild-type counterpart, beta 1A, remained unchanged. Tumors exhibiting different Gleason's patterns showed that beta 1C was down-regulated in comparison with the benign tissue regardless of the histological grade. Immunoblotting analysis, using affinity-purified antibodies specific for beta 1C, was performed, in a quantitative manner, to compare beta 1C expression in benign and tumor prostate tissue. The results showed that beta 1C was expressed in benign prostate tissue whereas it was undetectable in prostate adenocarcinoma. Taken together, these data show that beta 1C integrin down-regulation in prostate tissues correlates with a neoplastic phenotype consistent with its in vitro growth-inhibitory properties. These findings indicate a novel pathophysiological role for this integrin variant in tumorigenesis.
Indexed as
Identifiers
8780381PMC1865133W1815541658What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.